Investment Thesis

.

Competitive Moat

characterized by intangible assets, particularly its extensive portfolio of patents and proprietary drugs that protect its market position. The company’s established brand and regulatory approvals create high switching costs for healthcare providers and patients, fostering patient loyalty and recurring revenue streams. This advantage is durable over the next 5-10 years, but it faces threats from biosimilars targeting HUMIRA and aggressive innovation from emerging biotech firms that could disrupt its dominance.

Growth Engine

Future revenue growth for AbbVie is expected to stem from its expanding line of therapies, particularly in immunology and oncology, with a total addressable market (TAM) projected to exceed $100 billion over the next decade. The successful launch and adoption of SKYRIZI and RINVOQ are already gaining traction, with significant market share uptake anticipated. Additionally, AbbVie’s strategic focus on acquisitions—such as the recent purchase of Allergan—enhances its pipeline and diversifies its offerings, driving both organic and acquisition-driven growth.